Monday, 26 Jun 2017

PsA/SpA

Datesort ascending Type Title Save
27 Aug 2016 Social Ixekizumab (Taltz), IL-17 inhibitor, better than Placebo, but same as Humira @24wks in treating psoriatic arthritis https://t.co/vFqF31oMLZ
24 Aug 2016 News Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
23 Aug 2016 Social Structural progression is low (~5%) in early SpA; Sacroiliitis risk factors were B27, smoking & MRI SI inflammation https://t.co/MWsxlbb6lt
23 Aug 2016 Social Confusing names: Spondylolysis, Spondylolisthesis, Spondylitis & Spondylosis explained. https://t.co/EfHzzsyENY
19 Aug 2016 Social Ankylosing spondylitis has 14% incr risk of cancer; GI tract (RR 1.20); M.myelomas (RR 1.92); lymphoma (RR 1.32) https://t.co/ggQyT7kyw3
16 Aug 2016 News Fewer Psoriasis Patients Satisfied with Current Treatments
05 Aug 2016 News Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?
04 Aug 2016 News RAPID3: An Effective Assessment Tool in Spondyloarthritis
25 Jul 2016 News Novel Rise of Combined Dermatology-Rheumatology Clinics
22 Jul 2016 News FDA Panel Recommends Brodalumab Approval in Psoriasis
20 Jul 2016 Social Taurog & Colbert review #AS, ankylosing spondylitis & #SpA Spondyloarthritis in current NEJM. https://t.co/L6lQSi9Gyn
18 Jul 2016 News SAPHO Syndrome Revisted
18 Jul 2016 Slide of the day Clinical Associations with Uveitis
18 Jul 2016 Social MTX in PsA yields min. Dz activity in <20%. MDA=5/7 SJC, PASI, entheses≤1, BSA≤3%, HAQ≤0.5, pt global≤20, Pt pain≤15 https://t.co/dO6qyys8yy
14 Jul 2016 Social in 428 SpA pts, BMI (obesity) has no effect on ASDAS. BMI weakly correlates w/ CRP, other PRO's. https://t.co/FcTfEicYpN
27 Jun 2016 Social RAPID3 gives similar outcome info to BASDAI and ASDAS in a cross sectional study of 85 AS patients https://t.co/uIfXJpB5s3
25 Jun 2016 News AS Diagnosis Linked to CVD Risk
17 Jun 2016 Social Swedish registries show (like RA) ankylosing spondylitis is assoc w/ 30%–50% increased risk of incident CV events. https://t.co/9B8CSxOEYi
13 Jun 2016 News No Increased Risk of Colitis Flares in Secukinumab Trials
12 Jun 2016 Social Drs Braun & van der Heidje review efficacy & imaging benefits of Cosentyz & Xeljanz in Ank Spondylitis at #EULAR2016 https://t.co/gM26e2x57t